FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely neurology, and concerns treating pathological syndrome specific for multiple sclerosis. That is ensured by administering a pharmaceutical composition containing an activated-potentiated form of human gamma-interferon (IFN-γ) antibodies and an activated-potentiated form of brain-specific protein S-100 antibodies.
EFFECT: therapeutic agent provides treating multiple sclerosis ensured by the synergetic action of the ingredients of the composition.
9 cl, 2 ex, 1 tbl, 4 dwg
